Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...

Camp4 Therapeutics Corporation’s CAMP share price has dipped by 18.47%, which has investors questioning if this is right time to buy.

German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Boston, USA-based biotech Averna Therapeutics (formerly known as Exsilio Therapeutics), revealed yesterday that it has ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

Camp4 Therapeutics Corporation’s CAMP share price has surged by 18.71%, which has investors questioning if this is right time to sell.